Why the study?
Do ACEIs or ARBs reduce the development of atrial fibrillation in patients with cardiovascular conditions?
Do ACEIs or ARBs reduce the development of atrial fibrillation in patients with cardiovascular conditions?
Treatment with ACEIs or ARBs significantly reduces the risk of developing atrial fibrillation, with the greatest benefit seen in patients with heart failure or after electrical cardioversion.
Supports RAAS inhibition for AF prevention in CV patients; confirms benefit and extends evidence to HF and post-cardioversion settings.
The renin-angiotensin-aldosterone system (RAAS) has emerged as an important hormonal system in the initiation and pathogenesis of atrial fibrillation (AF). Therefore, angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are emerging as novel drugs for the prevention of AF. A meta-analysis of 11 randomized, controlled, parallel-design clinical trials evaluating effect of ACEIs or ARBs on the development of AF was performed. Treatment with ACEIs or ARBs reduced the relative risk (RR) of AF in patients with hypertension by 23% [RR 0.769, P < 0.001, 95% confidence interval (CI) 0.686-0.862] and by 11% in patients after myocardial infarction (RR 0.898, P < 0.05, 95% CI 0.814-0.992). Reduction in AF was greatest in patients after electrical cardioversion (RR 0.491, P < 0.001, 95% CI 0.334-0.720) and in patients with heart failure (RR 0.684, P < 0.001, 95% CI 0.594-0.787). Overall, inhibition of the RAAS reduced the RR of AF by 19% (RR 0.810, P < 0.001, 95% CI 0.759-0.865).
No takes yet. Share an insight, caveat, or question.
Jibrini et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: